Navegar

Colección

Datos Estadísticas

Artículo

Gao, Z.-G.; Jeong, L.S.; Moon, H.R.; Kim, H.O.; Choi, W.J.; Shin, D.H.; Elhalem, E.; Comin, M.J.; Melman, N.; Mamedova, L.; Gross, A.S.; Rodriguez, J.B.; Jacobson, K.A. "Structural determinants of efficacy at A3 adenosine receptors: Modification of the ribose moiety" (2004) Biochemical Pharmacology. 67(5):893-901
La versión final de este artículo es de uso interno. El editor solo permite incluir en el repositorio el artículo en su versión post-print. Por favor, si usted la posee enviela a
Consulte el artículo en la página del editor
Consulte la política de Acceso Abierto del editor

Abstract:

We have found previously that structural features of adenosine derivatives, particularly at the N6- and 2-positions of adenine, determine the intrinsic efficacy as A3 adenosine receptor (AR) agonists. Here, we have probed this phenomenon with respect to the ribose moiety using a series of ribose-modified adenosine derivatives, examining binding affinity and activation of the human A3 AR expressed in CHO cells. Both 2′- and 3′-hydroxyl groups in the ribose moiety contribute to A3 AR binding and activation, with 2′-OH being more essential. Thus, the 2′-fluoro substitution eliminated both binding and activation, while a 3′-fluoro substitution led to only a partial reduction of potency and efficacy at the A3 AR. A 5′-uronamide group, known to restore full efficacy in other derivatives, failed to fully overcome the diminished efficacy of 3′-fluoro derivatives. The 4′-thio substitution, which generally enhanced A3 AR potency and selectivity, resulted in 5′-CH2OH analogues (10 and 12) which were partial agonists of the A3 AR. Interestingly, the shifting of the N6-(3- iodobenzyl)adenine moiety from the 1′- to 4′-position had a minor influence on A3 AR selectivity, but transformed 15 into a potent antagonist (16) (Ki=4.3nM). Compound 16 antagonized human A 3 AR agonist-induced inhibition of cyclic AMP with a KB value of 3.0nM. A novel apio analogue (20) of neplanocin A, was a full A 3 AR agonist. The affinities of selected, novel analogues at rat ARs were examined, revealing species differences. In summary, critical structural determinants for human A3 AR activation have been identified, which should prove useful for further understanding the mechanism of receptor activation and development of more potent and selective full agonists, partial agonists and antagonists for A3 ARs. © 2003 Elsevier Inc. All rights reserved.

Registro:

Documento: Artículo
Título:Structural determinants of efficacy at A3 adenosine receptors: Modification of the ribose moiety
Autor:Gao, Z.-G.; Jeong, L.S.; Moon, H.R.; Kim, H.O.; Choi, W.J.; Shin, D.H.; Elhalem, E.; Comin, M.J.; Melman, N.; Mamedova, L.; Gross, A.S.; Rodriguez, J.B.; Jacobson, K.A.
Filiación:Laboratory of Bioorganic Chemistry, Natl. Inst. Diabet. Digest. Kidney, National Institutes of Health, Bethesda, MD 20892, United States
Laboratory of Medicinal Chemistry, College of Pharmacy, Ewha Womans University, Seoul 120-750, South Korea
Departamento de Quimica Organica, Fac. de Ciencias Exactas y Naturales, Ciudad Universitaria, Buenos Aires RA-1428, Argentina
Palabras clave:A3 adenosine receptor agonist; A3 adenosine receptor antagonist; Adenylyl cyclase; Nucleosides; Partial agonist; Phospholipase C; adenosine A3 receptor agonist; adenosine A3 receptor antagonist; ribose; animal cell; article; CHO cell; controlled study; drug efficacy; drug inhibition; drug potency; drug selectivity; drug transformation; nonhuman; priority journal; receptor affinity; receptor intrinsic activity; species difference; substitution reaction
Año:2004
Volumen:67
Número:5
Página de inicio:893
Página de fin:901
DOI: http://dx.doi.org/10.1016/j.bcp.2003.10.006
Título revista:Biochemical Pharmacology
Título revista abreviado:Biochem. Pharmacol.
ISSN:00062952
CODEN:BCPCA
CAS:ribose, 34466-20-1, 50-69-1, 93781-19-2
Registro:https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_00062952_v67_n5_p893_Gao

Referencias:

  • Fredholm, B.B., Ijzerman, A.P., Jacobson, K.A., Klotz, K.N., Linden, J., International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors (2001) Pharmacol. Rev., 53, pp. 527-552
  • Zhou, Q.Y., Li, C., Olah, M.E., Johnson, R.A., Stiles, G.L., Civelli, O., Molecular cloning and characterization of an adenosine receptor: The A3 adenosine receptor (1992) Proc. Natl. Acad. Sci. U.S.A., 89, pp. 7432-7436
  • Liang, B.T., Jacobson, K.A., A physiological role of the adenosine A3 receptor: Sustained cardioprotection (1998) Proc. Natl. Acad. Sci. U.S.A., 95, pp. 6995-6999
  • Auchampach, J.A., Ge, Z.D., Wan, T.C., Moore, J., Gross, G.J., A3 adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs (2003) Am. J. Physiol. Heart Circ. Physiol., 285, pp. 607-H613
  • Von Lubitz, D.K., Lin, R.C., Popik, P., Carter, M.F., Jacobson, K.A., Adenosine A3 receptor stimulation and cerebral ischemia (1994) Eur. J. Pharmacol., 263, pp. 59-67
  • Fedorova, I.M., Jacobson, M.A., Basile, A., Jacobson, K.A., Behavioral characterization of mice lacking the A3 adenosine receptor: Sensitivity to hypoxic neurodegeneration (2003) Cell Mol. Neurobiol., 23, pp. 431-447
  • Avila, M.Y., Stone, R.A., Civan, M.M., Knockout of A3 adenosine receptors reduces mouse intraocular pressure (2002) Invest. Ophthalmol. Vis. Sci., 43, pp. 3021-3026
  • Gao, Z.G., Jacobson, K.A., 2-Chloro-N6-cyclopentyladenosine, adenosine A1 receptor agonist, antagonizes the adenosine A3 receptor (2002) Eur. J. Pharmacol., 443, pp. 39-42
  • Gao, Z.G., Kim, S.K., Biadatti, T., Chen, W., Lee, K., Barak, D., Kim, S.G., Jacobson, K.A., Structural determinants of A3 adenosine receptor activation: Nucleoside ligands at the agonist/antagonist boundary (2002) J. Med. Chem., 45, pp. 4471-4484
  • Gao, Z.G., Blaustein, J.B., Gross, A.S., Melman, N., Jacobson, K.A., N6-Substituted adenosine derivatives: Selectivity, efficacy, and species differences at A3 adenosine receptor (2003) Biochem. Pharmacol., 65, pp. 1675-1684
  • Van Tilburg, E.W., Von Frijtag Drabbe Künzel, J., De Groote, M., Vollinga, R.C., Lorenzen, A., Ijzerman, A.P., N6,5′-Disubstituted adenosine derivatives as partial agonists for the human adenosine A3 receptor (1999) J. Med. Chem., 42, pp. 1393-1400
  • Van Tilburg, E.W., Van Der Klein, P.A., Von Frijtag Drabbe Kunzel, J., De Groote, M., Stannek, C., Lorenzen, A., Ijzerman, A.P., 5′-O-alkyl ethers of N6,2-substituted adenosine derivatives: Partial agonists for the adenosine A1 and A3 receptors (2001) J. Med. Chem., 44, pp. 2966-2975
  • Gao, Z.G., Chen, A., Barak, D., Kim, S.K., Müller, C.E., Jacobson, K.A., Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor (2002) J. Biol. Chem., 277, pp. 19056-19063
  • Lim, M.H., Kim, H.O., Moon, H.R., Lee, S.J., Chun, M.W., Gao, Z.G., Melman, N., Jeong, L.S., Design, synthesis and binding affinity of 3′-fluoro analogues of Cl-IB-MECA as adenosine A3 receptor ligands (2003) Bioorg. Med. Chem. Lett., 13, pp. 817-820
  • Jeong, L.S., Jin, D.Z., Moon, H.R., Kim, H.O., Chun, M.W., Melman, N., Gao, Z.G., Jacobson, K.A., N6-Substituted D-4′-thioadenosine-5′-uronamides: Potent and selective agonists at the human A3 adenosine receptor (2003) J. Med. Chem., 46, pp. 3775-3777
  • Bradford, M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding (1976) Anal. Biochem., 72, pp. 248-254
  • Olah, M.E., Gallo-Rodriguez, C., Jacobson, K.A., Stiles, G.L., 125I -4-Aminobenzyl-5′-N-methylcarboxamidoadenosine, a high affinity radioligand for the rat A3 adenosine receptor (1994) Mol. Pharmacol., 45, pp. 978-982
  • Nordstedt, C., Fredholm, B.B., A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid (1990) Anal. Biochem., 189, pp. 231-234
  • Cheng, Y.-C., Prusoff, W.H., Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction (1973) Biochem. Pharmacol., 22, pp. 3099-3108
  • Comin, M.J., Rodriguez, J.B., First synthesis of (-)-neplanocin C (2000) Tetrahedron, 56, pp. 4639-4649
  • Moon, H.R., Kim, H.O., Lee, K.M., Chun, M.W., Kim, J.H., Jeong, L.S., Stereoselective synthesis of a novel apio analogue of neplanocin a as potential S-adenosylhomocysteine hydrolase inhibitor (2002) Org. Lett., 4, pp. 3501-3503
  • Volpini, R., Costanzi, S., Lambertucci, C., Taffi, S., Vittori, S., Klotz, K.N., Cristalli, G., N6-Alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A3 receptor and a starting point for searching A2B ligands (2002) J. Med. Chem., 45, pp. 3271-3279
  • Arunlakshana, O., Schild, H.O., Some quantitative uses of drug antagonists (1959) Br. J. Pharmacol. Chemother., 14, pp. 48-58
  • Bridges, A.J., Bruns, R.F., Ortwine, D.F., Priebe, S.R., Szotek, D.L., Trivedi, B.K., N6-[2-(3,5-Dimethoxyphenyl)-2-(2-methylphenyl)ethyl]adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor (1988) J. Med. Chem., 31, pp. 1282-1285
  • Gallo-Rodriguez, C., Ji, X.D., Melman, N., Siegman, B.D., Sanders, L.H., Orlina, J., Fischer, B., Jacobson, K.A., Structure-activity relationships of N6-benzyladenosine- 5′-uronamides as A3-selective adenosine agonists (1994) J. Med. Chem., 37, pp. 636-646
  • Parsons, M., Young, L., Lee, J.E., Jacobson, K.A., Liang, B.T., Distinct cardioprotective effects of adenosine mediated by differential coupling of receptor subtypes to phospholipases C and D (2000) FASEB J., 14, pp. 1423-1431
  • Takano, H., Bolli, R., Black Jr., R.G., Kodani, E., Tang, X.L., Yang, Z., Bhattacharya, S., Auchampach, J.A., A1 or A3 adenosine receptors induce late preconditioning against infarction in conscious rabbits by different mechanisms (2001) Circ. Res., 88, pp. 520-528
  • Lee, H.T., Emala, C.W., Protective effects of renal ischemic preconditioning and adenosine pretreatment: Role of A1 and A3 receptors (2000) Am. J. Physiol. Renal Physiol., 278, pp. 380-387
  • Lee, H.T., Ota-Setlik, A., Xu, H., D'Agati, V.D., Jacobson, M.A., Emala, C.W., A3 adenosine receptor knockout mice are protected against ischemia- and myoglobinuria-induced renal failure (2003) Am. J. Physiol. Renal Physiol., 284, pp. 267-273

Citas:

---------- APA ----------
Gao, Z.-G., Jeong, L.S., Moon, H.R., Kim, H.O., Choi, W.J., Shin, D.H., Elhalem, E.,..., Jacobson, K.A. (2004) . Structural determinants of efficacy at A3 adenosine receptors: Modification of the ribose moiety. Biochemical Pharmacology, 67(5), 893-901.
http://dx.doi.org/10.1016/j.bcp.2003.10.006
---------- CHICAGO ----------
Gao, Z.-G., Jeong, L.S., Moon, H.R., Kim, H.O., Choi, W.J., Shin, D.H., et al. "Structural determinants of efficacy at A3 adenosine receptors: Modification of the ribose moiety" . Biochemical Pharmacology 67, no. 5 (2004) : 893-901.
http://dx.doi.org/10.1016/j.bcp.2003.10.006
---------- MLA ----------
Gao, Z.-G., Jeong, L.S., Moon, H.R., Kim, H.O., Choi, W.J., Shin, D.H., et al. "Structural determinants of efficacy at A3 adenosine receptors: Modification of the ribose moiety" . Biochemical Pharmacology, vol. 67, no. 5, 2004, pp. 893-901.
http://dx.doi.org/10.1016/j.bcp.2003.10.006
---------- VANCOUVER ----------
Gao, Z.-G., Jeong, L.S., Moon, H.R., Kim, H.O., Choi, W.J., Shin, D.H., et al. Structural determinants of efficacy at A3 adenosine receptors: Modification of the ribose moiety. Biochem. Pharmacol. 2004;67(5):893-901.
http://dx.doi.org/10.1016/j.bcp.2003.10.006